Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01857934Phase 2Completed

Therapy for Children With Advanced Stage Neuroblastoma

Role: collaborator

NCT01625351Phase 1Completed

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Role: collaborator

NCT05188170Phase 1Recruiting

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Role: collaborator

NCT04334863Phase 1Completed

WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors

Role: collaborator

NCT02343224Phase 2Completed

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Role: collaborator

NCT01576692Phase 1Completed

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Role: collaborator

All 6 trials loaded